EZ Traders Forum

[RIGATONI]

~MLHP News...


Millenia Hope Receives Funding in Private Placement
Further Funding Anticipated
MONTREAL, May 10, 2005 /PRNewswire-FirstCall via COMTEX/ --
Millenia Hope Inc., a Delaware Bio-pharma corporation (OTC Bulletin Board: MLHP; Berlin: MLF), today announced the execution of an agreement with an unaffiliated investor, in connection with the sale of shares of restricted common stock of Millenia Hope and the receipt of funding in the amount of $600,000 US. This is the completion of the first stage of an anticipated much larger private placement, being arranged on a "best efforts" basis by Private Consulting Group, Inc. ("PCG"), a registered securities broker dealer headquartered in Portland, Oregon.

Funding from the various investors involved could reach as much as $22,000,000 US, to be raised on a "best efforts" basis by PCG. The receipt of additional funding is subject to certain milestones being reached by Millenia. Various tranches of the common stock are anticipated to be purchased at pre- determined prices.

"This is an important alliance for Millenia Hope, given the investors' excellent affiliations with financial institutions, the worldwide business community and humanitarian organizations around the globe," stated Leonard Stella, CEO of Millenia Hope.

Part of the proceeds of the investment will be used to complete Millenia's current clinical program with MMH Malarex(TM)/MMH 18(TM) in Africa, under protocols monitored by the World Health Organization (WHO), UNICEF, and the Pasteur Institute.

In addition, Millenia Hope intends to further maximize shareholder value by seeking out and acquiring additional products to diversify its product base.

Mr. Stella continued, "There are 300-500 million malaria-infected individuals globally; three (3) million die annually, of which 1 million are children under five (5) years of age. An effective malaria cure is urgently needed. In many regions 70% or more of malaria strains are resistant to existing medications, and the WHO in no longer funding products like chloroquine to which malaria is resistant. MMH Malarex(TM)/MMH 18(TM) cures malaria in those regions where resistant strains are prevalent. This investment will greatly aid Millenia Hope in its primary mission, to save lives in regions afflicted with the devastating effects of this deadly disease."

Stella concluded, "This funding will enhance Millenia's goal to be a global force in the treatment of malaria."

About Millenia Hope

Millenia Hope develops innovative treatments and quality products that will increase the quality of life, provide tools in the fight against devastating diseases, and promote healthier lives. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.

Safe Harbor Statement

Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.

For more information, please contact:

Mr. Hugo Valente
Tel: [phone]r 514 288-8822
Fax: [phone]

http://www.milleniahope.com


[e-mail]

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com .

SOURCE Millenia Hope Inc.

Mr. Hugo Valente, Millenia Hope, [phone], [phone], Fax:
[phone],
[e-mail]


http://www.prnewswire.com


--------------------------------------------------------------------------------

Copyright (C) 2005 PR Newswire. All rights reserved.

News provided by